Pediatric Nephrology

, Volume 28, Issue 4, pp 611–616

Ghrelin and leptin pathophysiology in chronic kidney disease

Review

Abstract

Ghrelin is an orexigenic hormone with additional effects on the regulation of inflammation and the cardiovascular system. It may play an important role in the pathogenesis of cachexia/protein-energy wasting (PEW), inflammation and cardiovascular complications in chronic kidney disease (CKD). There are three circulating gene products of ghrelin, namely, acyl ghrelin, des-acyl ghrelin and obestatin, each with individual distinct functions. Perturbations of these circulating ghrelin proteins impact the overall milieu of CKD. Leptin is an anorexigenic hormone which is secreted from the adipocytes and interacts with ghrelin and other appetite-regulating hormones. Leptin also plays a role in regulating inflammation and the cardiovascular system. Indeed, ghrelin and leptin may play yin-and-yang roles in CKD pathophysiology. Clinical trials involving the use of the mimetics or antagonists of these hormones are limited to short-term phase I/II studies. Further understanding of their interactions in CKD pathophysiology is needed for potential large-scale clinical trials, which may impact the quality of life and survival of patients with CKD.

Keywords

Ghrelin Leptin Chronic kidney disease Cachexia Inflammation Cardiovascular Mortality 

References

  1. 1.
    Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, Klein C, Hsueh AJ (2005) Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s effects on food intake. Science 310(5750):996–999PubMedCrossRefGoogle Scholar
  2. 2.
    Tschöp M, Smiley DL, Heiman ML (2000) Ghrelin induces adiposity in rodents. Nature 407(6806):908–913PubMedCrossRefGoogle Scholar
  3. 3.
    Cowley MA, Smith RG, Diano S, Tschop M, Pronchuk N, Grove KL, Strasburger CJ, Bidlingmaier M, Esterman M, Heiman ML, Garcia-Segura LM, Nillni EA, Mendez P, Low MJ, Sotonyi P, Friedman JM, Liu H, Pinto S, Colmers WF, Cone RD, Horvath TL (2003) The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 37:649–661PubMedCrossRefGoogle Scholar
  4. 4.
    Cummings DE, Frayo RS, Marmonier C, Aubert R, Chapelot D (2004) Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues. Am J Physiol Endocrinol Metab 287:E297–E304PubMedCrossRefGoogle Scholar
  5. 5.
    Masuda Y, Tanaka T, Inomata N, Ohnuma N, Tanaka S, Itoh Z, Hosoda H, Kojima M, Kangawa K (2000) Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun 276:905–908PubMedCrossRefGoogle Scholar
  6. 6.
    Van der Lely AJ, Tschöp M, Heiman ML, Ghigo E (2004) Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 25(3):426–457PubMedCrossRefGoogle Scholar
  7. 7.
    Frascarelli S, Ghelardoni S, Ronca-Testoni S, Zucchi R (2003) Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart. Basic Res Cardiol 98(6):401–405PubMedCrossRefGoogle Scholar
  8. 8.
    Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W, Hosoda H, Hirota Y, Ishida H, Mori H, Kangawa K (2001) Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 104(12):1430–1435PubMedCrossRefGoogle Scholar
  9. 9.
    Kawczynska-Drozdz A, Olszanecki R, Jawien J, Brzozowski T, Pawlik WW, Korbut R, Guzik TJ (2006) Ghrelin inhibits vascular superoxide production in spontaneously hypertensive rats. Am J Hypertens 19:764–767PubMedCrossRefGoogle Scholar
  10. 10.
    Morton GJ, Schwartz MW (2001) The NPY/AgRP neuron and energy homeostasis. Int J Obesity Relat Metab Disord 25(Suppl 5):S56–S62CrossRefGoogle Scholar
  11. 11.
    Denver RJ, Bonett RM, Boorse GC (2011) Evolution of leptin structure and function. Neuroendocrinology 94(1):21–38PubMedCrossRefGoogle Scholar
  12. 12.
    Cohen MM (2006) Role of leptin in regulating appetite, neuroendocrine function, and bone remodeling. Am J Med Genet A 140A:515–524CrossRefGoogle Scholar
  13. 13.
    Woods AJ, Stock MJ (1996) Leptin activation in hypothalamus. Nature 381:745PubMedCrossRefGoogle Scholar
  14. 14.
    Abdel-Malek ZA (2001) Melanocortin receptors: their functions and regulation by physiological agonists and antagonists. Cell Mol Life Sci 58:434–441PubMedCrossRefGoogle Scholar
  15. 15.
    Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292–295PubMedCrossRefGoogle Scholar
  16. 16.
    Park HY, Kwon HM, Lim HJ, Hong BK, Lee JY, Park BE, Jang Y, Cho SY, Kim HS (2001) Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 33(2):95–102PubMedCrossRefGoogle Scholar
  17. 17.
    Kirwin SM, Bhandari V, Dimatteo D, Barone C, Johnson L, Paul S, Spitzer AR, Chander A, Hassink SG, Funanage VL (2006) Leptin enhances lung maturity in the fetal rat. Pediatr Res 60(2):200–204PubMedCrossRefGoogle Scholar
  18. 18.
    Cervero A, Domínguez F, Horcajadas JA, Quiñonero A, Pellicer A, Simón C (2006) The role of the leptin in reproduction. Curr Opin Obstet Gynecol 18(3):297–303PubMedCrossRefGoogle Scholar
  19. 19.
    Hamrick MW, Ferrari SL (2008) Leptin and the sympathetic connection of fat to bone. Osteoporos Int 19(7):905–912PubMedCrossRefGoogle Scholar
  20. 20.
    Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, Klein AS, Bulkley GB, Bao C, Noble PW, Lane MD, Diehl AM (1998) Leptin regulates proinflammatory immune responses. FASEB J 12:57–65PubMedGoogle Scholar
  21. 21.
    La Cava A, Alviggi C, Matarese G (2004) Unraveling the multiple roles of leptin in inflammation and autoimmunity. J Mol Med (Berl) 82(1):4–11CrossRefGoogle Scholar
  22. 22.
    Barazzoni R, Gortan Cappellari G, Zanetti M, Guarnieri G (2012) Ghrelin and muscle metabolism in chronic uremia. J Ren Nutr 22(1):171–175PubMedCrossRefGoogle Scholar
  23. 23.
    Yoshimoto A, Mori K, Sugawara A, Mukoyama M, Yahata K, Suganami T, Takaya K, Hosoda H, Kojima M, Kangawa K, Nakao K (2002) Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am Soc Nephrol 13:2748–2752PubMedCrossRefGoogle Scholar
  24. 24.
    Jarkovská Z, Rosická M, Krsek M, Sulková S, Haluzik M, Justová V, Lacinová Z, Marek J (2005) Plasma ghrelin levels in patients with end-stage renal disease. Physiol Res 54:403–408PubMedGoogle Scholar
  25. 25.
    Iglesias P, Díez JJ, Reyest MJF, Codoceo R, Fidalgo PA, Bajo MA, Aguilera A, Selgas R (2005) Serum ghrelin concentrations in patients with chronic renal failure undergoing dialysis. Clin Endocrinol 64:68–73CrossRefGoogle Scholar
  26. 26.
    Büscher AK, Büscher R, Hauffa BP, Hoyer PF (2010) Alterations in appetite-regulating hormones influence protein-energy wasting in pediatric patients with chronic kidney disease. Pediatr Nephrol 25(11):2295–2301PubMedCrossRefGoogle Scholar
  27. 27.
    Naufel MF, Bordon M, de Aquino TM, Ribeiro EB, de Abreu Carvalhaes JT (2010) Plasma levels of acylated and total ghrelin in pediatric patients with chronic kidney disease. Pediatr Nephrol 25(12):2477–2482PubMedCrossRefGoogle Scholar
  28. 28.
    Suneja M, Murry DJ, Stokes JB, Lim VS (2011) Hormonal regulation of energy-protein homeostasis in hemodialysis patients: an anorexigenic profile that may predispose to adverse cardiovascular outcomes. Am J Physiol Endocrinol Metab 300(1):E55–E64PubMedCrossRefGoogle Scholar
  29. 29.
    Cumin F, Baum HP, De Gasparo M, Levens N (1997) Leptin is cleared from the circulation primarily by the kidney. Int J obes Relat Metab Disord 21:495–504PubMedCrossRefGoogle Scholar
  30. 30.
    Shankar A, Syamala S, Xiao J, Muntner P (2012) Relationship between plasma leptin level and chronic kidney disease. Int J Nephrol. 2012: 269532. doi:10.1155/2012/269532
  31. 31.
    Carrero JJ, Nakashima A, Qureshi AR, Lindholm B, Heimbürger O, Bárány P, Stenvinkel P (2011) Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. Kidney Int 79(7):749–756PubMedCrossRefGoogle Scholar
  32. 32.
    Deboer MD, Zhu X, Levasseur PR, Inui A, Hu Z, Han G, Mitch WE, Taylor JE, Halem HA, Dong JZ, Datta R, Culler MD, Marks DL (2008) Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 149:827–835PubMedCrossRefGoogle Scholar
  33. 33.
    Ogawa Y, Masuzaki H, Hosoda K, Aizawa-Abe M, Suga J, Suda M, Ebihara K, Iwai H, Matsuoka N, Satoh N, Odaka H, Kasuga H, Fujisawa Y, Inoue G, Nishimura H, Yoshimasa Y, Nakao K (1999) Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes 48(9):1822–1829PubMedCrossRefGoogle Scholar
  34. 34.
    Cheung W, Yu PX, Little BM, Cone RD, Marks DL, Mak RH (2005) Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 115(6):1659–1665PubMedCrossRefGoogle Scholar
  35. 35.
    Barazzoni R, Zanetti M, Stulle M, Mucci MP, Pirulli A, Dore F, Panzetta G, Vasile A, Biolo G, Guarnieri G (2008) Higher total ghrelin levels are associated with higher insulin-mediated glucose disposal in non-diabetic maintenance hemodialysis patients. Clin Nutr 27:142–149PubMedCrossRefGoogle Scholar
  36. 36.
    Muscaritoli M, Molfino A, Chiappini MG, Laviano A, Ammann T, Spinsanti P, Melchiorri D, Inui A, Alegiani F, Rossi Fanelli F (2007) Anorexia in hemodialysis patients: the possible role of des-acyl ghrelin. Am J Nephrol 27(4):360–365PubMedCrossRefGoogle Scholar
  37. 37.
    Daschner M, Tönshoff B, Blum WF, Englaro P, Wingen AM, Schaefer F, Wühl E, Rascher W, Mehls O (1998) Inappropriate elevation of serum leptin levels in children with chronic renal failure. European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. J Am Soc Nephrol 9(6):1074–1079PubMedGoogle Scholar
  38. 38.
    Besbas N, Ozaltin F, Coşkun T, Ozalp S, Saatçi U, Bakkaloğlu A, El Nahas AM (2003) Relationship of leptin and insulin-like growth factor I to nutritional status in hemodialyzed children. Pediatr Nephrol 18(12):1255–1259PubMedCrossRefGoogle Scholar
  39. 39.
    Stenvinkel P, Lindholm B, Lönnqvist F, Katzarski K, Heimbürger O (2000) Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol 11:1303–1309PubMedGoogle Scholar
  40. 40.
    Van Tellingen A, Grooteman MP, Schoorl M, ter Wee PM, Bartels PC, Schoorl M, van der Ploeg T, Nubé MJ (2004) Enhanced long-term reduction of plasma leptin concentrations by super-flux polysulfone dialysers. Nephrol Dial Transplant 19(5):1198–1203PubMedCrossRefGoogle Scholar
  41. 41.
    Wynne K, Giannitsopoulou K, Small CJ, Patterson M, Frost G, Ghatei MA, Brown EA, Bloom SR, Choi P (2005) Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J Am Soc Nephrol 16:2111–2118PubMedCrossRefGoogle Scholar
  42. 42.
    Ashby DR, Ford HE, Wynne KJ, Wren AM, Murphy KG, Busbridge M, Brown EA, Taube DH, Ghatei MA, Tam FW, Bloom SR, Choi P (2009) Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. Kidney Int 76(2):199–206PubMedCrossRefGoogle Scholar
  43. 43.
    Mak RH, Cheung W, Cone RD, Marks DL (2006) Leptin and inflammation-associated cachexia in chronic kidney disease. Kidney Int 69(5):794–797PubMedCrossRefGoogle Scholar
  44. 44.
    Granado M, Priego T, Martin AI, Villanua MA, Lopez-Calderon A (2005) Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab 288:E486–E492PubMedCrossRefGoogle Scholar
  45. 45.
    Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, Lillard JW Jr, Taub DD (2004) Ghrelin inhibits leptin- and activation induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 114:57–66PubMedGoogle Scholar
  46. 46.
    Grunfeld C, Zhao C, Fuller J, Pollack A, Moser A, Friedman J, Feingold KR (1996) Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 97:2152–2157PubMedCrossRefGoogle Scholar
  47. 47.
    Mafra D, Farage NE, Lobo JC, Stockler-Pinto MB, Leal VO, Carvalho DP, Leite M Jr (2010) Relationship between total ghrelin and inflammation in hemodialysis patients. Peptides 32(2):358–361PubMedCrossRefGoogle Scholar
  48. 48.
    Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr (1998) Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32:853–906PubMedCrossRefGoogle Scholar
  49. 49.
    Mitsnefes MM (2012) Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 23(4):578–585PubMedCrossRefGoogle Scholar
  50. 50.
    Correia ML, Morgan DA, Sivitz WI, Mark AL, Haynes WG (2001) Leptin acts in the central nervous system to produce dose-dependent changes in arterial pressure. Hypertension 37(3):936–942PubMedCrossRefGoogle Scholar
  51. 51.
    Beltowski J, Wójcicka G, Marciniak A, Jamroz A (2004) Oxidative stress, nitric oxide production, and renal sodium handling in leptin-induced hypertension. Life Sci 74(24):2987–3000PubMedCrossRefGoogle Scholar
  52. 52.
    Chou CC, Bai CH, Tsai SC, Wu MS (2010) Low serum acylated ghrelin levels are associated with the development of cardiovascular disease in hemodialysis patients. Intern Med 49(19):2057–2064PubMedCrossRefGoogle Scholar
  53. 53.
    Małyszko J, Wołczyński S, Małyszko J, Myśliwiec M (2002) Leptin correlates with some hemostatic parameters in CAPD patients. Nephron 92(3):721–724PubMedCrossRefGoogle Scholar
  54. 54.
    Agata J, Masuda A, Takada M, Higashiura K, Murakami H, Miyazaki Y, Shimamoto K (1997) High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens 10(10 Pt 1):1171–1174PubMedCrossRefGoogle Scholar
  55. 55.
    Mak RH, Cheung WW (2011) Is ghrelin a biomarker for mortality in end-stage renal disease? Kidney Int 79(7):697–699PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2012

Authors and Affiliations

  1. 1.Division of Pediatric NephrologyUniversity of California San Diego–Rady Children’s HospitalSan DiegoUSA
  2. 2.Division of Pediatric NephrologyUniversity of California San DiegoLa JollaUSA

Personalised recommendations